SCHEMBL5650786

SCHEMBL5650786

CCN(CC)CCCNC(=O)c1ccc(-c2nc3c(Cl)cc(C(F)(F)F)cc3[nH]2)c(C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 3/20 0.47
HTT P42858 3/20 0.43
TP53 P04637 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HDAC4 P56524 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
TACR2 P21452 1/20 0.41
TACR1 P25103 1/20 0.41
MCHR1 Q99705 1/20 0.40
GAA P10253 2/20 0.40
KDM4E B2RXH2 1/20 0.40
GLA P06280 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CBFB Q13951 1/20 0.39
PDE2A O00408 1/20 0.39
FLT3 P36888 1/20 0.39
PPARD Q03181 1/20 0.39
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5653019 0.92 METAP2 (0.46) METAP2HTTTP53SMN1; SMN2HDAC4
SCHEMBL5651716 0.90 METAP2 (0.49) METAP2HTTTP53SMN1; SMN2HDAC4
SCHEMBL5647607 0.89 HTT (0.43) METAP2HTTTP53SMN1; SMN2HDAC4
SCHEMBL5651375 0.88 FLT3 (0.50) METAP2TACR2TACR1CBFBFLT3
SCHEMBL5647974 0.88 HDAC6 (0.50) HTTTP53SMN1; SMN2HDAC4HDAC2
SCHEMBL5650796 0.87 HTT (0.45) METAP2HTTTP53SMN1; SMN2HDAC4
SCHEMBL5651747 0.86 FLT3 (0.53) METAP2HTTTP53SMN1; SMN2HDAC4
SCHEMBL5651756 0.84 FLT3 (0.47) METAP2HTTTP53SMN1; SMN2HDAC4
SCHEMBL5649255 0.82 PRSS12 (0.50) HTTTP53SMN1; SMN2HDAC6GAA
SCHEMBL5651653 0.81 HTT (0.49) HTTTP53SMN1; SMN2HDAC6GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 METAP2 3311/4885HTT 4354/4885TP53 4051/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.